CLINICAL_TRIALS ClinicalTrials.gov record with results posted

Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05523440
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-06-04T12:58:48.523993+00:00
Published At: 2026-06-03T00:00:00+00:00
Record Updated At: 2026-06-03
Results Posted At: 2026-06-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Endometrial Carcinoma", "Recurrent Ovarian Carcinoma", "ARID1A Gene Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-06-03"
protocolSection.identificationModule.nctId: "NCT05523440"
protocolSection.identificationModule.officialTitle: "Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-06-03"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.